Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: HUM stock price vs LDOS: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at LDOS's multiple
Needs LDOS P/E.
Implied fair value · at HUM's multiple
Needs HUM P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Ten period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
HUMANA INC · implied price per share
Bear
$238.74
Base
$269.81
Bull
$310.28
Leidos Holdings, Inc. · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
UNITEDHEALTH GROUP INC
HUM vs UNH
Elevance Health, Inc.
HUM vs ELV
CVS HEALTH Corp
HUM vs CVS
Cigna Group
HUM vs CI
CENTENE CORP
HUM vs CNC
Oscar Health, Inc.
HUM vs OSCR
INTERNATIONAL BUSINESS MACHINES CORP
HUM vs IBM
Accenture plc
HUM vs ACN
LOCKHEED MARTIN CORP
HUM vs LMT
NORTHROP GRUMMAN CORP /DE/
HUM vs NOC
GENERAL DYNAMICS CORP
HUM vs GD
ZEBRA TECHNOLOGIES CORP
HUM vs ZBRA
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe HUM can materially expand margins and sustain double-digit revenue growth, then hold or add only selectively because the current 37.5x P/E already embeds a strong recovery scenario; otherwise, relative valuation favors LDOS and argues for caution on HUM.
HUM trades at a materially higher earnings multiple than LDOS, with a P/E of 37.5x versus 10.6x, despite lower profitability metrics. The model’s implied price of $104.69 versus the current $369.28 suggests a -71.7% downside on this relative valuation approach.
Supporting Metrics
